Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PreTreg: Tregs and Anti-CD20 Antibody in Pediatric Patients With Presymptomatic Type 1 Diabetes
NCT06688331Phase 2Recruiting
- Sponsor
- PolTREG
- Start
- Mar 2025
- Primary completion
- Dec 2032
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in type 1 diabetes mellitus (T1D), sponsored by PolTREG. Started Mar 2025; status: recruiting.
02
Drugs
rituximab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06688331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06688331.